文献速递炎症性肠病

美国炎症性肠病生物制剂治疗的市场份额与费用

Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
PubMed 文献 · Aliment Pharmacol Ther · 2017-11-22

基于Truven MarketScan数据库分析2007-2015年美国415405例炎症性肠病(IBD)患者的门诊用药趋势。生物制剂市场份额持续上升,克罗恩病(CD)使用比例从21.8%升至43.8%,溃疡性结肠炎(UC)从5.1%升至16.2%。生物制剂费用占比从2007年72.9%升至2015年85.7%。

要点

  • 9年间生物制剂使用比例CD从21.8%升至43.8%,UC从5.1%升至16.2%。
  • 生物制剂患者年均费用从2007年25275美元升至2015年36051美元。
  • 生物制剂费用占比从2007年72.9%升至2015年85.7%。

核心结论

  • 美国IBD门诊药物费用绝大部分归因于生物制剂使用的增加,尽管使用生物制剂的患者相对少数。

研究设计与样本

  • 分析Truven MarketScan数据库2007-2015年克罗恩病和溃疡性结肠炎患者,共415405例(CD 188842例,UC 195183例,未定型结肠炎31380例,女性54.67%)。

主要发现

  • CD患者使用生物制剂比例从21.8%升至43.8%,UC从5.1%升至16.2%。
  • CD患者免疫调节剂和5-氨基水杨酸使用小幅下降,其他类别包括仅使用糖皮质激素作为主要IBD药物保持相对稳定。
  • 生物制剂患者年均费用从2007年25275美元升至2015年36051美元。
  • 儿童生物制剂患者年均费用从2007年23616美元升至2015年41109美元。
  • 所有患者中生物制剂费用占比从2007年72.9%升至2015年85.7%,儿童从2007年81.7%升至2015年94.9%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-world data quantifying the costs of increasing use of biologics in inflammatory bowel disease (IBD) are unknown. AIM: To determine the outpatient IBD drug utilization trends, relative market share, and costs in the USA during a 9-year period. METHODS: The Truven MarketScan® Database was analysed for patients with Crohn's disease (CD) and ulcerative colitis (UC) during 2007-2015. National drug codes were used to identify prescription drugs; Healthcare Common Procedure Coding System J-codes were used to capture biologic out-patient infusions. Proportion of drug usage, relative market share and per-member per-year (PMPY) costs were analysed for biologics, immunomodulators, 5-ASAs and corticosteroids. RESULTS: In 415 405 patients (188 842 CD; 195 183 UC; 31 380 indeterminate colitis; 54.67% female), utilization trends show a consistent rise in the market share of biologics during the 9-year study period. The proportion of patients using biologics increased from 21.8% to 43.8% for CD and 5.1%-16.2% for UC. This contrasts a small decrease in immunomodulator and 5-ASA use for CD and relative constancy of other classes including corticosteroids-only use as primary IBD medication from 2007 to 2015. The average biologic-taking patient accounted for $25 275 PMPY in 2007 and $36 051 PMPY in 2015. The average paediatric biologic-taking patient accounted for $23 616 PMPY in 2007 and $41 109 PMPY in 2015. In all patients, the share of costs for biologics increased from 72.9% in 2007 to 85.7% in 2015 (81.7% in 2007 to 94.9% in 2015 in paediatrics). CONCLUSION: The vast majority of costs allocated to out-patient IBD medications in the USA is attributed to increasing use of biologic therapies despite the relative minority of biologic-taking patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yu H, MacIsaac D, Wong JJ, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2017. PMID: 29164650. doi:10.1111/apt.14430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。